What are the effects and potential risks of anastrozole (aromatase inhibitor) in men?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Anastrozole Effects in Men

Anastrozole is NOT FDA-approved for use in men and carries significant risks, particularly bone loss, despite its off-label use for male infertility and hypogonadism. 1

FDA-Approved Use and Critical Warning

Anastrozole is FDA-approved only for postmenopausal women with breast cancer. The drug label explicitly states it "does not work in women with breast cancer who have not gone through menopause (premenopausal women)" and warns against use in pregnancy 1. There is no FDA approval for male use.

Off-Label Use in Men: Clinical Context

Despite lack of FDA approval, anastrozole is used off-label in men for two primary indications:

1. Male Infertility with Abnormal Testosterone-to-Estradiol Ratio

The 2025 EAU guidelines acknowledge that aromatase inhibitors (including anastrozole) can improve hormonal and semen parameters in infertile men, though they emphasize the need for prospective randomized controlled trials 2. The mechanism involves:

  • Blocking estrogen production by inhibiting aromatase enzyme
  • Reducing negative feedback on the hypothalamus
  • Increasing GnRH pulses and FSH production
  • Potentially improving spermatogenesis 2

Evidence shows: Anastrozole significantly increases sperm concentration, total sperm count, LH, FSH, and testosterone levels while reducing estradiol 3. However, the quality of supporting studies remains low 2.

2. Elevated Estradiol During Testosterone Therapy

In men on testosterone replacement therapy (TRT), anastrozole 0.5 mg three times weekly effectively reduces elevated estradiol levels (median reduction from 65 to 22 pg/mL) without compromising testosterone levels 4. Only 2.6-3% of men on TRT require this intervention 4.

Serious Risks and Adverse Effects

Bone Health: The Primary Concern

The most significant risk is bone mineral density (BMD) loss. In a 1-year randomized controlled trial of older men with low testosterone:

  • PA spine BMD decreased from 1.121 to 1.102 g/cm² in the anastrozole group
  • Placebo group showed BMD increase from 1.180 to 1.189 g/cm²
  • The difference was statistically significant (P = 0.0014) 5

Critical finding: Aromatase inhibition does NOT improve skeletal health in aging men with low testosterone levels 5. This contradicts the theoretical benefit of increased testosterone, demonstrating that estrogen suppression dominates the skeletal effect.

Cardiovascular Considerations

Short-term studies (12 weeks) show anastrozole does NOT adversely affect:

  • Lipid profiles
  • Inflammatory markers (CRP, IL-6)
  • Adhesion molecules (ICAM-1, VCAM-1)
  • Insulin sensitivity 6

However, the 2025 EAU guidelines list "drug-induced aromatase activity blockade" as a recognized cause of hypogonadism 7, suggesting long-term concerns.

Other Documented Side Effects

Based on FDA labeling (from female studies) and male research:

  • Bone fractures (spine, hip, wrist) 1
  • Elevated cholesterol 1
  • Liver inflammation and dysfunction 1
  • Skin reactions (lesions, ulcers, blisters) 1
  • Joint pain and arthritis 1
  • Hot flashes 1

Clinical Decision Algorithm

For male infertility:

  • Consider only if T/E2 ratio is abnormal
  • Use lowest effective dose
  • Monitor bone density if treatment exceeds 12 weeks
  • Recognize evidence quality is low 2

For elevated estradiol on TRT:

  • Initiate only if E2 >60 pg/mL (regardless of symptoms) OR E2 40-60 pg/mL with symptoms 4
  • Dose: 0.5 mg three times weekly 4
  • Monitor E2, testosterone, and bone density
  • Consider discontinuing 2-7 days before assisted reproduction procedures 3

Contraindications:

  • Do NOT use with tamoxifen (reduces anastrozole efficacy) 1
  • Do NOT use with estrogen-containing medications 1
  • Avoid in men with pre-existing osteoporosis 1

Critical Pitfall

The most common error is failing to monitor bone health. While short-term studies (12 weeks) showed no bone turnover marker changes 8, longer-term use (1 year) demonstrated clear BMD loss 5. Baseline and serial DEXA scans are mandatory for any man on anastrozole beyond 3 months.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.